LifeMD, Inc. announced that it is now offering Foundayo (orforglipron) to eligible patients through its weight management program. Foundayo, developed by Eli Lilly and Company, is a once daily oral treatment for adults with obesity or overweight with weight-related medical problems. Foundayo is available to eligible LifeMD patients through the Company?s integration with LillyDirect, which enables prescriptions to be fulfilled and shipped directly to patients. The starting self-pay price for Foundayo is $149 per month for the initial dosage.
Patients with eligible commercial insurance may pay as little as $25 per month through a Lilly savings card, and Medicare coverage is anticipated to begin July 2026. The FDA approved Foundayo on April 1, 2026, making it the second oral GLP-1 therapy approved for weight management. The addition of Foundayo expands LifeMD?s offerings of branded GLP-1 therapies from both Lilly and Novo Nordisk and reinforces LifeMD?s position as a destination for clinically guided weight management care with FDA-approved medications.
Foundayo is available to eligible patients through the LifeMD weight management program, which provides comprehensive support including virtual consultations with LifeMD?s clinical team, access to diagnostic testing, secure messaging through a personalized patient portal, and educational resources on diet and lifestyle changes that are important for sustained weight loss and metabolic health. Eligible patients can learn more and schedule a consultation at LifeMD.com.
